Platelet Activation Affecting the Rate of Vascular Access Patency

• Conditions: Hemodialysis Fistula Thrombosis; Platelet Activation

• Registration Number: NCT05165797
• Lead Sponsor: Korea University Anam Hospital

Brief Summary

In the case of cardiovascular diseases such as coronary artery disease, cerebrovascular disease, and peripheral arterial disease, there are many studies that the use of antiplatelet agents is very helpful in improving the vascular patency rate, but there are not many studies on the use of antiplatelet agents in the dialysis approach. The basis for use is insufficient. There is a lack of research on whether maintaining a state in which platelet activation is suppressed is helpful in improving dialysis access patency. Therefore, we conducted this study to determine whether the degree of platelet activation affects the patency of vascular access.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-01
• Status Verified: 2021-12
• Study First Submitted: 2021-12-08
• Study First Submitted QC: 2021-12-08
• Last Update Submitted: 2021-12-08
• Study First Posted: 2021-12-21
• Last Update Posted: 2021-12-21
• Primary Completion: 2021-12-31
• Study Completion: 2022-07-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Patients 19 years of age or older who are undergoing hemodialysis during renal replacement therapy
• Patients undergoing arteriovenous fistula formation and hemodialysis to the affected area
• Patients who have the ability and willingness to consent to participate in the clinical study, have signed the consent form in accordance with the appropriate procedures, and can visit and participate in the clinical study as planned

Read More

Exclusion Criteria

• Patients who failed to start hemodialysis with an arteriovenous fistula within 3 months
• Patients who have had stent implantation or surgery during the study period due to cardiovascular disease
• Patients with severe hepatic impairment
• Patients with coagulopathy and liver disease associated with clinically significant bleeding risk
• Patients with clinically significant bleeding or bleeding risk
• Patients who underwent artificial heart valve replacement requiring anticoagulant administration
• Patients with pulmonary embolism who are hemodynamically unstable or require thrombolysis or pulmonary embolization.
• Pregnant and lactating women

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Vascular access primary patency	1 month	Time from vascular access creation until hemodialysis related procedure

Secondary Outcome Measures

Name	Time	Method
Vascular access secondary patency	1 month	Time from vascular access creation until hemodialysis failure

Trial Locations

Locations (1)

Korea university anam hospital; 🇰🇷 Seoul, Non US/Canada, Korea, Republic of